Wall Street analyst estimates for Acumen Pharmaceuticals, Inc. (ABOS): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-11 | $-0.43 | ||
| 2026-08-11 | $-0.45 | $-0.36 | -25.2% |
| 2026-05-12 | $-0.33 | $-0.40 | +18.1% |
| 2026-03-26 | $-0.41 | $-0.50 | +18.0% |
| 2025-11-12 | $-0.44 | $-0.63 | +30.2% |
| 2025-08-12 | $-0.68 | $-0.54 | -25.9% |
| 2025-05-13 | $-0.48 | $-0.56 | +14.3% |
| 2025-03-27 | $-0.62 | $-0.47 | -31.9% |
Valuation Ratios
| Price / Book | 3.39 |
| EV / EBITDA | -2.01 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $1.7M | $1.4M | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $8.6M | $8.0M | $12.3M | 0 | 0 | 0 | 0 |
| Gross Profit | -$6.9M | -$6.6M | -$12.3M | 0 | 0 | 0 | 0 |
| Research & Development | $8.6M | $8.0M | $12.3M | $32.4M | $42.3M | $93.8M | $104.9M |
| Selling, General & Admin | $926000 | $1.4M | $7.3M | $12.9M | $18.8M | $20.2M | $18.9M |
| Operating Expenses | $926000 | $1.4M | $7.3M | $45.2M | $61.1M | $114.0M | $123.8M |
| Operating Income | -$7.8M | -$7.9M | -$19.6M | -$45.2M | -$61.1M | -$114.0M | -$123.8M |
| EBITDA | 0 | -$7.9M | -$100.6M | -$42.7M | -$51.6M | -$98.1M | -$116.9M |
| Interest Expense | 0 | 0 | 0 | 0 | $581000 | $4.1M | $4.2M |
| Pre-tax Income | -$7.9M | -$7.3M | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$7.9M | -$7.3M | -$100.6M | -$42.9M | -$52.4M | -$102.3M | -$121.3M |
| EPS | $-0.20 | $-0.26 | $-2.63 | $-1.06 | $-1.08 | $-1.71 | $-2.00 |
| EPS (Diluted) | $-0.27 | $-0.26 | $-2.63 | $-1.06 | $-1.08 | $-1.71 | $-2.00 |
| Shares Outstanding (Diluted) | $28.7M | $28.7M | $38.3M | $40.6M | $48.6M | $60.0M | $60.6M |
Price
| Price | $2.61 |
| Market Cap | $189M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ACTU · AGEN · ALEC · FATE · INO · IRD · MCRB
Explore sector: Healthcare · Biotechnology
More sections of ABOS: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks